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Replacement of a diseased organ with an autologously derived tissue is an ideal therapy for some medical
problems. However, it is difficult to recreate many adult human tissues in vitro due to the functionally necessary
architecture of most organs and the lack of understanding of methods to direct the development of the organ of
interest. The parathyroid gland is ideal for in vitro organ development because this gland is relatively simple, is
transplantable, and is commonly affected by a surgical complication rather than an autoimmune disease. We
have investigated thymus as a source of autologous endoderm and parathyroid-like precursor cells. Human
thymus cells were treated with a differentiation protocol we developed with human embryonic stem cells (The
Bingham Protocol) that utilizes timed exposures to Activin A and soluble Sonic hedgehog (Shh). We incre-
mentally changed the protocol to optimize the differentiation of the thymus cells into parathyroid-like cells. The
final protocol used 50ng/mL Activin A and 100ng/mL Shh over 13 weeks. The differentiated cells expressed the
parathyroid markers parathyroid hormone (PTH), calcium sensing receptor, chemokine receptor type-4 (CXCR4),
and chorian-specific transcription factor (GCM2) as measured by reverse transcription–polymerase chain reaction
and PTH enzyme-linked immunosorbent assay. Cultured thymus cells without Activin A or Shh exposure did not
secrete PTH nor express similar markers. The differentiated cells released PTH, which was suppressed in response
to increased calcium concentration. The chemically differentiated cells did not form tumors in immune-compro-
mised mice. Our protocol recreated cells with markers of parathyroid tissue that responded as parathyroid cells to
physiologic stimuli. This approach is a further step toward a strategy to restore parathyroid function using
autologous cells that were directed to differentiate by nongenetic in vitro manipulation.
Introduction
Replacement of a diseased organ with regeneratedautologous tissue can be an ideal therapy for some
medical problems. However, it is difficult to recreate many
adult human tissues in vitro due to the architecture necessary
for the functionality of most organs or to autoimmune dis-
eases that could destroy the replacement organ.
The four parathyroid glands are small, delicate structures
that share their blood supply with the thyroid gland. Para-
thyroid cells detect and regulate serum calcium levels. Be-
cause the parathyroid glands can be difficult to identify in
situ, accidental loss of parathyroid gland function (hypopa-
rathyroidism) is the most frequent permanent complication
of thyroid and parathyroid surgery. In current clinical
practice, devascularized parathyroid tissue can be mechani-
cally disrupted into small bits and inserted into tissue
pockets where the cells survive on diffused nutrients until
neovascularization occurs. Resumption of measurable, nor-
mal parathyroid function occurs in 6–10 weeks postgrafting
for patients who otherwise have no endogenous parathyroid
function. The rate of complete normalization of parathyroid
function after autograft of parathyroid tissue is 50%–95%,1
and the grafted parathyroid tissue responds normally to
changes in serum calcium concentration. Unfortunately,
unless damage to the parathyroid glands is recognized in the
operating room, autografting cannot be performed.
Even though prevention of hypoparathyroidism by auto-
grafting damaged parathyroids is widely recognized as the
best approach, the rate of permanent hypoparathyroidism
after thyroid surgery is nearly 14% in population-based se-
ries2–4 though the occurrence is much lower in series from
expert surgeons (0.5%–4.0%).5–7 The chronic, detrimental
effects of hypoparathyroidism on bone, teeth, skin, and nails
are well documented.8 Hypoparathyroidism results in
chronic hypocalcemia and a low-turnover bone disease that
are poorly managed by currently available replacement
methods, which include multiple daily doses of vitamin D
analogues and calcium salts. Replacement of parathyroid
hormone (PTH) itself is available as teriparatide (Forteo,
Lilly), a 1–34 N-terminal protein fragment of PTH; however,
the serum half-life of synthetic PTH is less than 5min. While
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the overall treatment plan for hypoparathyroidism can be
effective, studies have shown that treatment regimens with
multiple daily doses, with drugs that can cause unwanted side
effects, or that have an exorbitant cost, greatly reduce the pa-
tient adherence to the treatment regimen.9–12 Since replace-
ment therapy for hypoparathyroidism (1) requires multiple
daily doses of calcium, vitamin D, and Forteo; (2) requires high
doses of calcium that can cause kidney stones, constipation,
dry mouth, a continuing headache, increased thirst, irritability,
loss of appetite, depression, a metallic taste in the mouth, and
fatigue; and (3) may include Forteo, which can cost $900–2100
per month; the management plan is often ineffective and could
be improved by organ replacement therapy.
Many of the challenges of organ replacement therapy are
avoided during parathyroid replacement because of the na-
ture of the parathyroid glands. Complete function of the
parathyroid gland is contained within each cell,1,3 the organs
have very limited mass, and the cells can be grafted to het-
erotopic locations.13–15 Also, the parathyroids are an organ
system that is affected by a surgical complication rather than
a physiological condition or autoimmune disease. The sim-
plicity of the parathyroid gland focuses the treatment chal-
lenges on the development of the autologous replacement
cells and not on the development of glandular architecture or
on protection from autoimmunity.
Our ultimate goal is to isolate autologous human pro-
genitor cells that can be induced to function as parathyroid
tissue and that can be grafted as autologous cells. In humans,
the thymus develops from the same primordium as the
parathyroid glands.1 Thus, we have investigated thymus as
a source of autologous endoderm and parathyroid-like
precursor cells. No prior research has been performed to
investigate the possible differentiation of thymus into para-
thyroid cells, although some cells in the thymus normally
express parathyroid markers. However, clinical experience
shows that parathyroid marker-expressing cells in the thy-
mus are not able to replace parathyroid function in situ in
spite of physiologic stimulus due to hypoparathyroidism.
We have previously developed a protocol for nongenetic
manipulation of human embryonic stem (hES) cells that in-
duces expression of the parathyroid markers PTH, calcium
sensing receptor (CaSR), chemokine receptor type-4 (CXCR4),
and chorian specific transcription factor (GCM2).16,17 Our hy-
pothesis in the current work was that a protocol similar to our
hESC protocol could be used to induce endogenous precursor
cells from thymus to change in similar ways. Our studies show
that a subset of human thymus cells can be induced through
nongenetic manipulation to express parathyroid markers. The
trans-differentiated cells expressed both thymus and parathy-
roid lineage-specific transcription factors and released PTH in
low calcium conditions and elevated calcium concentration in
culture suppressed PTH release. Our data suggest that this
strategy may be capable of restoring parathyroid function for a
patient using in vitro trans-differentiated cells.
Materials and Methods
Thymus cell isolation
Discarded thymus from pediatric cardiac operations was
obtained from the operating room and immediately dissoci-
ated using the procedure by Mouiseddine et al.18 While we
have human studies approval to also use adult thymus in
these studies, pediatric thymus is more cellular than adult,
easier to obtain since it is discarded tissue, and does not have
to go through pathology evaluation before use, which yields
less fresh tissue. Briefly, T cells are released by pressure with
the back of a syringe from the thymus tissue, which is covered
in HBSS (Hank’s balanced salt solution). Tissue is minced and
transferred from the HBSS to a triple enzyme mixture19 (0.1%
collagenase, 0.002% deoxyribonuclease, and 0.01% hyalur-
anidase). The tissue is dissociated in a gentleMACs dissociator
(Miltenyi) using the Spleen 2 program (fraction 1). The tissue is
incubated at 37C with gentle agitation for 15min to yield a
second fraction that Mouseddine has characterized as thymic
stromal cells (TSC), enriched for multipotent mesenchymal
stem cells. The lightly dissociated tissue is further separated
using the gentleMACs Spleen 1 program and passed through a
0.22mm cell screen to separate the cells from the fibrous tissue;
these cells are called the thymic epithelial cell (TEC) fraction.
This cell fraction from the thymus dissociation process (TEC)
was used for further experiments based on expression of
precursor markers of interest.
Differentiation protocols
The TEC from thymus were incubated using the Bingham
protocol. Briefly, cells were incubated in RPMI 1640 (In-
vitrogen) with 5% fetal bovine serum (FBS). Cells were kept
in culture with or without cholera toxin to slow fibroblast
growth and with Activin A (100 ng/mL; R&D Systems) and
Sonic hedgehog (Shh; 100 ng/mL; R&D Systems). Cells were
tested for marker expression and PTH secretion at each
major time point in the protocol. The protocol was modified
in subsequent experiments to optimize marker expression.
The differentiated, attached thymus cells were incubated
at various time points in Epilife (Gibco) with additions of
pen-strep and EPILIFE defined growth supplement (EDGS,
Gibco). No FBS was used in this assay. Commercial calcium
chloride (Invitrogen) was used for calcium suppression
testing. Medium changes and sampling occurred at 24 h time
points or took place every 90min.
Polymerase chain reaction
Total RNA was isolated using TRIzol reagent. cDNA
synthesis was performed using the ReactionReady First
Strand cDNA synthesis kit (SuperArray). Polymerase chain
reactions (PCRs) were performed using primer sets previ-
ously published that span exon splicing sites.16,17 GAPD in-
ternal standards were used in each reaction. The PCR
protocol was one cycle at 95C for 15min, and then 30 cycles
of 15 s at 95C, 30 s at 55C, and 30 s at 72C with a final
extension of 7min at 72C.
Enzyme-linked immunosorbent assay
At each major time point of the differentiation protocol,
conditioned medium was collected and stored at -80C until
use. The medium was used in a commercial intact PTH ELISA
kit (Calbiotech). Cell number was not obtained as the condi-
tionedmediumwas taken from cells used in the next step of the
differentiation process. All samples were tested in triplicate.
Immunofluorescence
Thymus and parathyroid tissue were both dissociated
using the protocol described above. The red blood cells were
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lysed using Ack Lysing Buffer (Lonza) according to the
protocol. Cells were also harvested from tissue culture plastic
using TryPLE Select (Gibco). Cells were adhered to slides
using a Cytospin 4 (Thermo Shandon). Cells were fixed with
2% paraformaldehyde for 15min at 22C. For some experi-
ments, CaSR antibody (Catalog #SC-47741, Santa Cruz Bio-
tech) was applied for 1 h at 22C. Cells were permeabilized in
0.1% Triton X-100 for 6min at 22C. Cells were stained with
FoxN1 antibody (Catalog #SAB 2500416, Sigma Aldrich)
and/or with GCM2 antibody (custom antibody, Primm) for
1 h at 22C. Coverslips were mounted using ProLong Gold
antifade reagent (Invitrogen) containing 4¢,6-diamidino-2-
phenylindole (DAPI). Stains were observed in a fluorescent
microscope.
Results
Complete parathyroid gland differentiation is marked by
the specific expression of GCM2. Parathyroid cells are the
sole cells in the body that concomitantly produce PTH and
express the CaSR as part of their physiologic function to
control PTH production and serum calcium levels. Therefore,
GCM2, CaSR, and PTH expression represent the definitive
markers of the parathyroid cell phenotype to determine the
trans-differentiated state of these cells.
The thymus is often discarded during cardiac or neck
operations. To determine if human thymus would be a good
source of cells for our protocol, we isolated separate popula-
tions of thymus cells, including TSC and TEC, according to the
protocol by Mouiseddine et al.18 Reverse transcription (RT)–
PCR showed that all of the fractions had low levels of both
early endoderm and parathyroid markers, but the TEC fraction
had slightly increased expression of markers (Fig. 1). This
fraction also contained the most cells. To this end, all of the cells
from the TEC fraction were treated with our protocol devel-
oped for differentiation of hES cells (Bingham protocol).16,17
TEC that had been in the Bingham protocol for 6 or 10
days with varying amounts of Activin A (bracketing the
amount we used in previous studies16,17) were assessed by
RT-PCR to determine the expression of early endoderm and
parathyroid markers (Fig. 2). Cells in all three concentrations
FIG. 1. Thymus cells express early endoderm and/or
parathyroid markers. Human thymus was dissociated in a
series of steps according to Mouiseddine et al.18 Cells were
collected at each fractionation and subjected to reverse
transcription–polymerase chain reaction for the early endo-
derm markers Eya1 and Six 1 and the parathyroid markers
GCM2, CaSR, and parathyroid hormone (PTH). Glycer-
aldehyde 3-phosphate dehydrogenase was used as a loading
control. C, commercially available thymus RNA; P, para-
thyroid RNA; NT, no RNA template used in reaction. Thy-
mic stromal cells (TSC) were released in second fraction and
thymic epithelial cells (TEC) are released at the end of the
procedure. TEC cells were used in further studies as the
expression of appropriate markers was the highest.
FIG. 2. TEC cells could be induced to express higher levels
of parathyroid markers. TEC cells (Fig. 1) were treated with
the Bingham protocol using a constant dose of Sonic
hedgehog (Shh; 100 ng/mL) and varying concentrations of
Activin A. Cells were tested at day 6 and 10 for early en-
doderm and parathyroid marker expression. Cells from the
protocol expressed higher levels of parathyroid markers than
cells at baseline after isolation and from commercially pre-
pared human thymus RNA (Fig. 1).
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and on both days contained higher amounts of all markers
compared with untreated thymus.
Cells in the protocol that replicated throughout adhered to
the tissue culture plate during week 6. After adherence, the
cells took on an elongated phenotype similar to parathyroid
cells in culture (Fig. 3A). Conditioned medium was collected
from cells in all three Activin A concentrations at 6 weeks to
determine secreted PTH levels. An image of unstimulated
thymus cells is presented for comparison (Fig. 3B). Note the
structures that resemble thymic corpuscles present in the
unstimulated cells. These structures were not observed in
the cells that underwent the Bingham protocol. Static levels of
PTH secretion from cells that had been through the protocol
weremodest, similar to those observedwith hES cells that had
been in the protocol16,17 (data not shown). Calcium-regulated
PTH secretion was demonstrated when calcium was with-
drawn for 24h from the cells that had been in the protocol for
at least 6 weeks. There was a robust calcium-regulated PTH
response after treatment with 50ng/mL Activin A, half the
amount used to differentiate the hES cell16,17 (Fig. 3C). Based
on these data, 50 ng/mL Activin A was used in the remainder
of experiments. TEC were also kept in culture without the
FIG. 3. TEC cells from the Bingham protocol secreted PTH in a calcium-dependent manner. (A) Cells from the Bingham
protocol after they adhered to the tissue culture plate, at about 6 weeks. The cells took on the appearance of human
parathyroid cells in culture. (B) Thymus cells in culture without Activin A or Shh. The cells were small, did not adhere, and
formed thymic corpuscle-like structures. Picture was taken at same magnitude as cell pictures in (A) but was computer
magnified 3· to show cell morphology. Bar is 0.1mm. (C) TEC cells in the Bingham protocol for 10 weeks secreted PTH in a
calcium-dependent manner and had the most robust response in cells cultured with 50 ng/mL Activin A.
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addition of Activin A or Shh as controls but did not secrete
PTH under any conditions (data not shown).
Calcium-regulated PTH secretion was evaluated for tim-
ing and durability. TEC were placed in the Bingham protocol
with Activin A and Shh. Cells were allowed to grow for 10
days, 3 weeks, and 10 weeks. At each time point, calcium
concentrations were changed on identical plates, and the
conditioned medium was collected for determination of se-
creted PTH 24 h later. TEC in the Bingham protocol for up to
3 weeks did not secrete PTH (data not shown); however, the
cells had not yet adhered to the tissue culture plates. At 10
weeks, adherent cells secreted large amounts of PTH in re-
sponse to calcium withdrawal from the culture (Fig. 4A).
Levels typically reached 60–84pg/mL PTH after withdrawal
of calcium from the medium. This is slightly elevated from
normal for both serum PTH levels and for parathyroid cells
in culture that have calcium withdrawn (10–65pg/mL).20,21
Calcium concentrations between 0 and 0.1mM do not pro-
duce a change in PTH secretion. About 1 to 0.2mM calcium
regularly decreased the secreted PTH levels. Changes of
calcium concentrations over 90min, instead of 24 h, pro-
duced secreted PTH only at the 0mM concentration (Fig. 4B).
Using 50 ng/mL Activin A, we determined the optimal
concentration of Shh by bracketing the concentration we
used previously.11 After 10 days in the culture protocol, the
cells did not secrete any PTH, but by 4 weeks in culture, the
cells secreted PTH (Fig. 4A). At 8 weeks, when the cells had
fully adhered, the cells secreted PTH in response to calcium
withdrawal after growth in 100 ng/mL Shh (Fig. 4C).
Data in the literature22 suggest that parathyroid cells can
be cultured for long periods, but the cells were only useful
for experiments for about 1 week. Thus, we evaluated
whether growth with Activin A and Shh would allow
parathyroid cells to remain functional in vitro. We stained for
both CaSR and GCM2 and found that parathyroid cells after
2 weeks lose expression of CaSR protein. Activin A/Shh in
the culture medium allowed the parathyroid cells to main-
tain their parathyroid markers for longer periods (Fig. 5A).
Since parathyroid cells under these conditions could grow
and express these identifying proteins, we sought to deter-
mine if the TEC were trans-differentiating or were expanding
a subpopulation of parathyroid-like cells resident in the
thymus. We first evaluated TEC that had been in the Bing-
ham protocol for 14 weeks for CaSR and GCM2 expression
by immunostaining (Fig. 5B). TEC from the Bingham pro-
tocol maintained expression of both CaSR and GCM2.
However, evaluation of TEC after the Bingham protocol by
staining for lineage-specific transcription factors (FoxN1 for
thymus and GCM2 for parathyroid) makes the expansion of
thymic resident parathyroid cells unlikely (Fig. 5C). As a
control, we stained primary thymus cells for both tran-
scription factors (Fig. 5D), which showed robust staining for
FoxN1 but not GCM2. These data show that the majority of
the postprotocol TEC are unique in that they express defin-
itive markers of both thymus and parathyroid lineage in the
same cell. Note that some of the cells did not stain for ex-
pression of any marker and that some cells only stained for
expression of one of the markers, indicating that the cell
population is not pure.
To determine if our trans-differentiated cells produced
tumors in mice, we injected 1 · 104–1· 106 cells subcutane-
ously into both flanks of 5 RAG2 knock-out mice. We chose
FIG. 4. PTH release is robust and responsive to calcium
withdrawal after cells in the Bingham protocol become ad-
herent. (A) Cells that were not adherent (day 10) did not
secrete PTH. Cells at 4 weeks into the protocol did secrete
PTH in response to a change in Shh concentration to 50 ng/
mL. At week 10 of the protocol, adhered cells secreted PTH
although at 100 ng/mL Shh. (B) At 13 weeks, cells that un-
derwent the Bingham protocol had their medium changed to
low medium or high calcium levels for 90min. The condi-
tioned medium was then subjected to a PTH enzyme-linked
immunosorbent assay (ELISA). (C) Adherent cells after 8
weeks in the Bingham protocol were tested for PTH secretion
into their medium by intact PTH ELISA after incubation with
50 ng/mL Activin A and varying concentrations of Shh. Cells
became adherent around week 6 in culture. At week 8, the
medium was switched to contain various concentrations of
calcium. After 24 h, the conditioned medium was removed
and levels of intact PTH measured by ELISA.
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RAG2 knock-out mice as the immune-incompetent back-
ground for future in vivo experiments. At 3 months after
cellular transfer, none of the mice developed tumors. Because
our cells were not tagged in anyway, since we do not want
any form of genetic manipulation, we were unable to tell if
the cells were viable at the end of the experiment. We did
replate the cells remaining from the injections, and they did
adhere to tissue culture plates. Since the RAG2 knock-out
animals have functioning parathyroids, we did not test for
PTH secretion by our injected cells.
Discussion
In vitro differentiation of human cells for replacement of
organ function is a rapidly developing field. Most research is
centered on the addition of developmental genes to re-
differentiate cells. Unfortunately, although these genes can
drive redifferentiation of the cells, they also facilitate the
development of tumors when the redifferentiated cells are
placed in mice. Thus, new areas of research center on finding
nongenetic methods to drive cells toward redifferentiation.
Many of the challenges of organ replacement therapy are
avoided during parathyroid replacement because of the na-
ture of the parathyroid glands: (1) each parathyroid cell
contains the complete function of the organ, (2) no architec-
tural arrangement of parathyroid cells is needed to support
or enhance the function of the organ, (3) transplantation of a
small number of parathyroid cells reconstitutes normal
parathyroid function, and (4) patients who have lost this
function due to operative complication have no autoimmune
reactivity to their parathyroid tissue. Therefore, the para-
thyroid glands are an ideal system for laboratory-created
tissue replacement not only to treat diseases of the para-
thyroid glands but also as a model for the differentiation of
more complex organs. Given the advanced understanding of
the molecular markers of parathyroid organogenesis
FIG. 5. (Continued).
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in vivo23–42 and the appropriateness of parathyroid glands for
cellular replacement therapy, we have developed methods
for recreating parathyroid differentiation using less differ-
entiated cells as a starting point. Beginning with established
protocols for generating definitive endoderm from hES
cells,43 we differentiated the hES lines BGO1 and H1 to ex-
press pharyngeal endoderm markers by culturing with Ac-
tivin A and Shh in vitro.16,17 We optimized the culture
protocol by serial assessment of the expression of signaling
markers in the parathyroid development pathway. Cells that
went through the full differentiation protocol expressed the
parathyroid markers PTH, CaSR, CXCR4, and GCM2. The
differentiated cells also released PTH into the medium.
The hES cell lines were used only as a model system for the
development of the culture protocols because two main
barriers exist to using hES cells for further studies: (1) the
potential of these cells and their progeny for alloimmunity
and (2) the potential of the cells to form tumors. Building on
our observations with the in vitro differentiation of hES cell,
we were able to direct the differentiation of TEC into cells
with parathyroid function. The process that we detail here
results in novel cells that are not precisely the same as native
parathyroid cells. Individual cells express markers of both
thymus and parathyroid lineages, indicating that they are a
new cell type trans-differentiated from thymus precursors,
but that also have the unique identifying characteristics of
parathyroid cells.
Recently, Bonfanti et al.44 isolated embryonic rat thymus
and redifferentiated them into skin cells by placing them in
the presence of rat skin. Although they were able to
FIG. 5. TEC after the Bingham protocol express parathyroid markers and a parathyroid lineage-specific transcription factor.
Cells were adhered to slides using a cytospin, fixed, stained for CaSR (A, B), permeabilized, stained for FoxN1 (C, D) and for
GCM2 (A–D). (A) Parathyroid cells were cultured for 2 weeks with and without Activin A/Shh. Parathyroid cells without
Activin A/Shh readily lost their parathyroid markers, CaSR (red) and GCM2 (green). (B) TEC were plated in the Bingham
protocol, and after 3 weeks, the adherent cells (‘‘stuck 1’’) were isolated from the floating cells. The floating cells were replated
for 1 week and the resulting adherent cells (‘‘stuck 2’’) were cultured. ‘‘Both’’ refers to the total thymus population without
any attempt at isolating a particular cell type. After 14 weeks, the TEC expressed both CaSR (red) and GCM2 (green). (C) TEC
after 14 weeks in the Bingham protocol were stained for FoxN1 (green) and GCM2 (red). Many cells stained for both
transcription factors, indicating that the thymus cells were trans-differentiating. Arrows indicate double-positive cells. (D)
TEC stained for lineage-specific transcription factors Fox N1 (thymus-specific) and GCM2 (parathyroid-specific) without
extensive in vitro culture. As expected, the cells stained for FoxN1 (green) with rare cells staining for GCM2 (red). No cells
express both markers. Bottom two panels show merged pictures with and without DAPI. All pictures were taken at 50· .
Arrows indicate GCM2-only positive cells. DAPI, 4¢,6-diamidino-2-phenylindole. Bar is 0.1mm.
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redifferentiate thymus without genetic manipulation, our
studies have key differences. Importantly, the Bonfanti work
used embryonic rodent cells on cellular feeder layers. The
rodent cells may be a good model for protocol development
(rather than the hES cells that we used); however, the use of
cellular feeder layers would dramatically complicate even-
tual clinical applications. In addition, they used environ-
mental factors to create hair follicles, whereas we used
developmental factors to trans-differentiate into a functional
organ. However, their conclusion that the embryonic rat
thymus contains multipotent cells is echoed in our results
with developed human thymus.
The weaknesses of our study are (1) that the current
experiments are limited to thymus glands from young
children having operations for congenital cardiac anoma-
lies and (2) the cultures after differentiation are not likely to
contain solely parathyroid-like cells. First, the use of thy-
mus tissue from young children is defined both by con-
venience and cellularity. With a large number of pediatric
cardiac procedures performed in our institution, discarded
pediatric thymus is readily available. In addition, the pedi-
atric thymus is very cellular, so each specimen yields a large
amount of material to use for experiments. The weakness of
this is that the cellular populations in the pediatric thymus
may not be the same, or present in the same abundance, in
the adult thymus available from the people for whom this
strategy would be most applicable. Second, we have not
made any significant attempts in this group of studies to
isolate the parathyroid-like cells from others in culture. Our
fluorescent studies indicate that we have trans-differentiated
cells that subsequently make up about 50% of the culture.
Isolation of the precise subset will be important to allow
specific grafting of the best subset of cells, One strategy is to
separate the CaSR-expressing cells to provide as pure a
population as possible and then to focus on ways to maxi-
mize the PTH production of the differentiated cells.
Taken together, our data show that the postnatal thymus
contains cells capable of trans-differentiation into calcium-
sensitive PTH-secreting parathyroid-like cells. The presented
protocol uses human tissue, recreates a physiologically con-
trolled system (calcium-regulated PTH release), and does not
require genetic manipulation of cells. Thus, these data sug-
gest that it will be possible to restore a patient’s parathyroid
function using in vitro trans-differentiated cells.
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